Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autonomix MedicalAMIX -9.97%15 EV-to-EBIT is 0.47 as of Jul. 14, 2026. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Autonomix Medical ranks better than 98.28% on this metric.
Autonomix Medical (NAS:AMIX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Autonomix Medical's Enterprise Value for the quarter that ended in Mar. 2026 was $-2.56 Mil.
Autonomix Medical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autonomix Medical EV-to-EBIT Related Terms
Autonomix Medical EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Autonomix Medical's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Autonomix Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autonomix Medical EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autonomix Medical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Autonomix Medical's EV-to-EBIT falls into.
Autonomix Medical's current Enterprise Value is $-7.87 Mil.
Autonomix Medical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autonomix Medical (AMIX) has a EV-to-EBIT of 0.47 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Autonomix Medical and its competitors. According to the industry distribution chart, Autonomix Medical ranks #8 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 1.7%.
Is Autonomix Medical's EV-to-EBIT too high?
Autonomix Medical's current EV-to-EBIT is 0.47. The Medical Devices & Instruments industry median EV-to-EBIT is 18.74. Autonomix Medical's value of 0.47 is 97.5% below this industry median. Based on the distribution chart, Autonomix Medical ranks #8 out of 466 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's EV-to-EBIT compare to BJDX and LUDG?
According to the Medical Devices & Instruments industry distribution chart, Autonomix Medical ranks #8 out of 466 companies for EV-to-EBIT. This places Autonomix Medical in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.74. Autonomix Medical's value of 0.47 is 97.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.74, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autonomix Medical's current EV-to-EBIT of 0.47 is 97.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Autonomix Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autonomix Medical's current EV-to-EBIT is 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current EV-to-EBIT of 0.47. The current EV-to-EBIT is 0.47 and 97.5% below the Medical Devices & Instruments industry median of 18.74. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current EV-to-EBIT is 0.47 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score
Get the complete analysis for AMIX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMIX has been successfully added to your 
